1. Home
  2. APRE vs ELOG Comparison

APRE vs ELOG Comparison

Compare APRE & ELOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aprea Therapeutics Inc.

APRE

Aprea Therapeutics Inc.

HOLD

Current Price

$0.88

Market Cap

10.6M

Sector

Health Care

ML Signal

HOLD

ELOG

Eastern International Ltd. Ordinary Shares

N/A

Current Price

$0.99

Market Cap

12.4M

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
APRE
ELOG
Founded
2006
2006
Country
United States
China
Employees
8
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Integrated Freight & Logistics
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
10.6M
12.4M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
APRE
ELOG
Price
$0.88
$0.99
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$4.10
N/A
AVG Volume (30 Days)
448.0K
9.4K
Earning Date
05-13-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
21.22
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$6.84
Revenue Growth
N/A
N/A
52 Week Low
$0.55
$0.80
52 Week High
$2.22
$3.07

Technical Indicators

Market Signals
Indicator
APRE
ELOG
Relative Strength Index (RSI) 55.83 43.02
Support Level $0.90 $0.86
Resistance Level $0.98 $1.19
Average True Range (ATR) 0.10 0.05
MACD 0.01 0.01
Stochastic Oscillator 56.18 28.97

Price Performance

Historical Comparison
APRE
ELOG

About APRE Aprea Therapeutics Inc.

Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.

About ELOG Eastern International Ltd. Ordinary Shares

Eastern International Ltd is a holding company. The company operates through its subsidiary engaged in domestic and cross-border professional logistic services including project logistics and general logistics for company clients. Its project logistic services include Construction project logistics and special cargo logistics for large or precision equipment and General logistic services refer to the transportation, warehousing, loading and unloading, and distribution of ordinary products. Its segments are Transportation services and Warehouse subleasing services. The group generates the majority of its revenue from Transportation services.

Share on Social Networks: